Cogent Biosciences Inc
NASDAQ:COGT
Income Statement
Earnings Waterfall
Cogent Biosciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-208.1m
USD
|
Operating Income
|
-208.1m
USD
|
Other Expenses
|
15.7m
USD
|
Net Income
|
-192.4m
USD
|
Income Statement
Cogent Biosciences Inc
Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||
Revenue |
7
N/A
|
8
+10%
|
8
+5%
|
9
+5%
|
8
-5%
|
8
-3%
|
10
+21%
|
11
+9%
|
12
+14%
|
11
-8%
|
23
+104%
|
26
+18%
|
24
-10%
|
23
-3%
|
8
-66%
|
1
-89%
|
0
-63%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||||||||||||
Operating Expenses |
(30)
|
(33)
|
(35)
|
(36)
|
(39)
|
(42)
|
(46)
|
(51)
|
(54)
|
(54)
|
(55)
|
(53)
|
(47)
|
(92)
|
(90)
|
(90)
|
(99)
|
(61)
|
(76)
|
(94)
|
(113)
|
(130)
|
(148)
|
(160)
|
(171)
|
(194)
|
(208)
|
|
Selling, General & Administrative |
(4)
|
(4)
|
(5)
|
(5)
|
(6)
|
(7)
|
(7)
|
(9)
|
(10)
|
(10)
|
(11)
|
(12)
|
(12)
|
(15)
|
(17)
|
(18)
|
(20)
|
(20)
|
(20)
|
(21)
|
(22)
|
(24)
|
(26)
|
(27)
|
(29)
|
(32)
|
(34)
|
|
Research & Development |
(26)
|
(29)
|
(30)
|
(31)
|
(33)
|
(35)
|
(38)
|
(43)
|
(44)
|
(44)
|
(44)
|
(41)
|
(35)
|
(77)
|
(73)
|
(71)
|
(79)
|
(42)
|
(56)
|
(73)
|
(90)
|
(105)
|
(122)
|
(132)
|
(142)
|
(162)
|
(174)
|
|
Operating Income |
(23)
N/A
|
(25)
-10%
|
(26)
-4%
|
(27)
-4%
|
(30)
-13%
|
(34)
-11%
|
(36)
-6%
|
(41)
-13%
|
(42)
-3%
|
(43)
-3%
|
(32)
+26%
|
(26)
+18%
|
(23)
+12%
|
(69)
-193%
|
(82)
-20%
|
(89)
-8%
|
(99)
-11%
|
(61)
+38%
|
(76)
-23%
|
(94)
-25%
|
(113)
-20%
|
(130)
-15%
|
(148)
-14%
|
(160)
-8%
|
(171)
-7%
|
(194)
-13%
|
(208)
-7%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
4
|
6
|
9
|
11
|
13
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
7
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
8
|
9
|
2
|
3
|
3
|
3
|
3
|
4
|
6
|
5
|
5
|
3
|
|
Pre-Tax Income |
(22)
N/A
|
(25)
-10%
|
(25)
-4%
|
(26)
-3%
|
(29)
-12%
|
(33)
-11%
|
(35)
-6%
|
(39)
-14%
|
(41)
-4%
|
(43)
-4%
|
(32)
+26%
|
(26)
+18%
|
(23)
+12%
|
(61)
-165%
|
(75)
-22%
|
(80)
-8%
|
(90)
-11%
|
(59)
+34%
|
(72)
-23%
|
(91)
-26%
|
(110)
-20%
|
(126)
-15%
|
(140)
-12%
|
(148)
-6%
|
(157)
-6%
|
(178)
-13%
|
(192)
-8%
|
|
Net Income | ||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(22)
|
(25)
|
(25)
|
(26)
|
(29)
|
(33)
|
(35)
|
(39)
|
(41)
|
(43)
|
(32)
|
(26)
|
(23)
|
(61)
|
(75)
|
(80)
|
(90)
|
(59)
|
(72)
|
(91)
|
(110)
|
(126)
|
(140)
|
(148)
|
(157)
|
(178)
|
(192)
|
|
Net Income (Common) |
(22)
N/A
|
(25)
-10%
|
(26)
-4%
|
(26)
-3%
|
(30)
-12%
|
(33)
-11%
|
(35)
-6%
|
(39)
-14%
|
(41)
-4%
|
(43)
-4%
|
(32)
+26%
|
(26)
+18%
|
(23)
+12%
|
(61)
-165%
|
(179)
-193%
|
(185)
-3%
|
(194)
-5%
|
(163)
+16%
|
(72)
+56%
|
(91)
-26%
|
(110)
-20%
|
(126)
-15%
|
(140)
-12%
|
(148)
-6%
|
(157)
-6%
|
(178)
-13%
|
(192)
-8%
|
|
EPS (Diluted) |
-1.82
N/A
|
-3.32
-82%
|
-3.46
-4%
|
-10.33
-199%
|
-4.04
+61%
|
-4.37
-8%
|
-5.55
-27%
|
-5.25
+5%
|
-5.37
-2%
|
-5.57
-4%
|
-4.18
+25%
|
-3.48
+17%
|
-2.96
+15%
|
-6.2
-109%
|
-16.17
-161%
|
-5.29
+67%
|
-5.04
+5%
|
-4.09
+19%
|
-1.87
+54%
|
-2.02
-8%
|
-2.21
-9%
|
-1.8
+19%
|
-2.39
-33%
|
-2.09
+13%
|
-2.1
0%
|
-2.06
+2%
|
-2.42
-17%
|